A man in his early 60s with prior carotid endarterectomy (CEA) followed by interposition common carotid artery ...

A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents a patient may need, making it a safe and effective way to treat certain ...

For patients with symptomatic coronary artery disease, the best course of action often involves implanting a drug-eluting stent into the artery where a plaque buildup is blocking blood flow to the ...

Elixir Medical’s coronary implant, DynamX bioadaptor, has been proven to significantly reduce the risk of device-related cardiac events compared with current-generation drug-eluting stents in a ...

The FDA approved a new emergency stent device to treat perforations in the blood vessels of the heart, the agency’s first new treatment option in the indication in 17 years. Deep tears in coronary ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Treating narrowed or blocked heart arteries has evolved over the past 40 years. This week, the FDA approved the latest step in that evolution — a stent that dissolves away, leaving nothing behind.

Emerging evidence may help reshape antiplatelet and lipid strategies for the management of coronary artery disease.

A 42 years old male patient was admitted with resuscitated sudden cardiac death. Electrocardiogram revealed ST segment elevation in leads II, III, and aVF. After crossing the lesion with a floppy ...

The delivery of coronary artery stents is a procedure that affects over 1 million patients each year in the United States. With an aging population, the declining cost of stents and reimbursement ...

The role of endovascular therapy in patients with renal artery stenosis continues to be very controversial. Two reports have added notable findings to the growing body of evidence on this subject. The ...

Add Yahoo as a preferred source to see more of our stories on Google. Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial.